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PLGA–PEG copolymerAbstract Purpose: Amphotericin B (AmB) is an effective anti-fungal and anti-leishmanial agent.
However, AmB has low oral bioavailability (0.3%) and adverse effects (e.g., nephrotoxicity). The
objectives of this study were to improve the oral bioavailability by entrapping AmB in pegylated
(PEG) poly lactide co glycolide copolymer (PLGA–PEG) nanoparticles (NPs). The feasibility of
different surfactants and stabilizers on the mean particle size (MPS) and entrapment efficiency were
also investigated.
Materials and methods: NPs of AmB were prepared by a modified emulsification diffusion
method employing a vitamin E derivative as a stabilizer. Physicochemical properties and particle
size characterization were evaluated using Fourier Transform Infra-Red spectroscopy (FTIR), dif-
ferential scanning calorimetry, scanning electron microscopy and transmission electron microscopy.
Moreover, in vitro dissolution profiles were performed for all formulated AmB NPs.
Results: MPS of the prepared spherical particles of AmB ranged from 26.4 ± 2.9 to
1068 ± 489.8 nm. An increased stirring rate favored AmB NPs with a smaller MPS. There was a
significant reduction in MPS, drug content and drug release, when AmB NPs were prepared using
the diblock polymer PLGA–PEG with 15% PEG. Addition of three emulsifying agents poly vinyl
pyrrolidone (PVP), Vitamin E (TPGS) and pluronic F-68 to AmB formulations led to a significant
reduction in particle size and increase in drug entrapment efficiency (DEE) compared to addition
of PVP alone. FTIR spectroscopy demonstrated a successful loading of AmB to pegylated
Figure
In vitro Optimization of Amphotericin Oral Nanoparticles 291PLGA–PEG copolymers. PLGA–PEG copolymer entrapment efficiency of AmB was increased up
to 56.7%, with 92.7% drug yield. After a slow initial release, between 20% and 54% of AmB was
released in vitro within 24 h phosphate buffer containing 2% sodium deoxycholate and were best fit
Korsmeyer–Peppas model. In conclusion, PLGA–PEG diblock copolymer with 15% PEG pro-
duced a significant reduction (>70%) in MPS with highest drug content. The percentage of
PEG in the copolymer and the surfactant/stabilizer used had a direct effect on AmB release
in vitro, entrapment efficiency and MPS. These developed formulations are feasible, effective and
improved alternatives to other carriers for oral delivery of AmB.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Amphotericin B (AmB) is a macrocyclic polyee antibiotic
(Fig. 1). A deoxycholate-soluble salt of AmB (Fungizone)
is marketed for use as an intravenous infusion (IVI) formula-
tion and has been the gold standard drug treatment for sys-
temic fungal infections since 1953 (Dutcher, 1968). This
parenteral formulation is usually associated with several
adverse effects (AE) including fever, chilling, vomiting, head-
ache and nausea during administration (80% of the patients)
and nephrotoxicity (30% of the patients) after dosing
(Torrado et al., 2008; Van de Ven et al., 2012).
AmB possesses both hydrophobic (polyene hydrocarbon
chain) and hydrophilic (polyhydroxyl chain) domains as
shown in Fig. 1 (Lemke et al., 2005). This amphoteric nature
is responsible for its poor solubility in both aqueous and
organic solvents. It is classified (Biopharmaceutical Classifica-
tion System (BCS)) as a class IV compound (Me´nez et al.,
2007) with limited solubility and permeability properties due
to its high molecular weight of 924 Da, leading to a low bio-
availability if given orally 0.3% (Ouellette et al., 2004).
Different tactics have been investigated to reduce AmB
associated nephrotoxicity and other AE during Fungizone
administration. These include saline loading, alternative day
dosing and dose reduction, all with limited success. In the early
1990s, new generations of AmB formulations were developed
by replacing sodium deoxycholate with either phospholipids
(Abelcet) or cholesterol (Amphocil) or both (AmBisome)
(Adler-Moore and Proffitt, 2008; Torrado et al., 2008). These
AmB formulations have shown improved therapeutic indexes
in comparison with Fungizone. However, the high cost of
these formulations (12–40 times more expensive than1 Structure of AmB (a), 3-D mFungizone), the need of hospitalization for parenteral
administration and the acute AE have limited the widespread
use of these new formulations (Adler-Moore and Proffitt,
2008; Ibrahim et al., 2012).
Since oral preparations would reduce the requirement for
hospitalization during administration, and therefore the costs
associated with its use, the development of a safe oral formu-
lation of AmB has been investigated.
For oral administration, the drug must be able to cross the
gastrointestinal (GI) epithelium. Several formulations have
been described for AmB oral delivery. These include lipid-
based formulations, either a self-emulsifying drug delivery sys-
tem (SEDDS) or cochleates (multilayer structure consisting of
a continuous solid lipid bilayer sheet), nanosuspensions solid
lipid nanoparticles (SLNs) polymeric NPs and polymeric lipid
hybrid NPs (Patel et al., 2013).
In most cases, these formulations failed to increase the
absorption of orally administered AmB. However, the cochle-
ate formulation of AmB (Biodelivery Sciences, Inc., USA) was
reported to successfully facilitate the oral absorption, and bio-
availability of AmB (Ibrahim et al., 2012) and provided protec-
tion from both gastric acid degradation and efflux via P-
glycoprotein (P-gp). After showing a favorable outcome of
AmB formulation during phase I trial (February 2009)
(Ibrahim et al., 2012), the manufacturer has ascertained that
further AmB clinical trials would be underway. Another oral
lipid-based AmB formulation is currently in development
(iCo Therapeutics Inc., Canada), showing a 50-fold increase
in AmB solubility over its non-lipid equivalent formulation
(Ibrahim et al., 2012). This formulation and the cochleate for-
mulation were reported to result in reduced nephrotoxicity
compared to AmB intravenous infusion (Thornton andodel of AmB (Lemke et al., 2005).
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two formulations have undergone full clinical trials and to
date, it is unclear whether these formulations of AmB will lead
to commercial pharmaceuticals (Yang et al., 2012).
During the past few decades there has been an increasing
interest in the development of polymeric biodegradable NPs,
either natural or synthetic, for effective drug delivery
(Barratt, 2003; Ma et al., 2008). The polyesters are the most
widely used polymers in this class because of their biocompat-
ibility, non-immunogenicity and low toxicity. Typical poly-
meric biodegradable NPs include poly (lactic acid) (PLA),
poly (glycolic acid) (PGA), polycaprolactone (PCL) and their
copolymers such as poly (lactide)-co-(glycolide) (PLGA). They
are approved for use in vivo by the Food and Drug Adminis-
tration (FDA) (Parveen and Sahoo, 2008).
One of the major problems with the polymeric drug carrier
NPs is that they are rapidly eliminated from the blood stream
through phagocytosis by the reticuloendothelial system (RES)
(Stolnik et al., 1995; Owens and Peppas, 2006). Avoidance of
phagocytosis can be achieved through pegylation using
Poly(ethylene glycol) (PEG), i.e., formation of the so-called
‘‘stealth’’ NPs, which abrogate the rapid uptake by phagocytic
cells. PEG has been the most common hydrophilic blocking
agent used since it is readily hydrated, it has a high degree of
conformational flexibility and is biocompatible. The inner
hydrophobic block has shown greater variability depending
on the system being studied (Jee et al., 2012).
AmB has been conjugated to either PEG (Conover et al.,
2003) or PLGA alone (Fig. 2) (Nahar and Jain, 2009; Van
de Ven et al., 2012), which resulted in an increased water sol-
ubility, increased efficacy and less toxicity when compared to
the commercial AmB products.
Block copolymers comprise two or more homopolymer
subunits linked by covalent bonds. Block copolymers with
two or three distinct blocks are called diblock copolymers
and triblock copolymers, respectively. Amphiphilic block
copolymers have the ability to form various types of NPs
referred to as micelles, nanocapsules, nanospheres or core-cor-
ona NPs (Chen et al., 2011). Block copolymer micelles areFigure 2 The chemical structure poly[(D,L
Table 1 Composition of the use pegylated PLGA–PEG copolymer
Symbol Name Polymer type Composition
A RGPd 50105 Diblock PLGA–PEG 6000
B RGPt 50106 Triblock PLGA–PEG 6000-PL
C RGPd 50155 Diblock PLGA–PEG 6000
D RGPd 5055 Diblock PLGA–PEG 6000
E7 R 203 H Monoblock Poly(D,L-lactide)water-soluble, biocompatible nano-containers in the size range
of 10–100 nm characterized by a core-corona architecture in
which the core serves as a reservoir for the incorporation of
poorly water-soluble drugs, while the hydrophilic corona pro-
vides a protective interface between the core and the external
medium (Gaucher et al., 2010).
In this study, recently introduced copolymers (PLGA–
PEG copolymer ‘‘Resomer PEG’’ copolymers), that shown
to be biodegradable and biocompatible (Sinha et al., 2004)
were used. The development of PLGA–PEG copolymer
NPs as an AmB carrier for oral delivery formulations with
improved bioavailability and lower toxicity was investigated.
Phase I, which is presented here, has been focused on the
in vitro optimization of the NPs formulations. Screening pro-
cesses have utilized differential scanning calorimetry, particle
size determination using Zetasizer, surface morphology using
scanning electron microscopy and transmission electron
microscopy as well as Fourier Transform Infra-Red (FTIR)
characterization. NP yield, drug loading and in vitro AmB
release have been studied.2. Materials and methods
2.1. Polymer and chemicals
Amphotericin B (AmB) (99.8% purity) and Nicardipine
Hydrochloride (98% purity), the internal standard (IS), were
purchased from Sigma–Aldrich (St. Louis, MO, USA different
types of Poly(D,L-lactide-co-glycolide) (Table 1) were supplied
by Boehringer Ingelheim (Ingelheim, Germany). Miglyol-812
neutral oil was obtained from Sasol (GmbH, Germany,). Vita-
min E (TPGS-NF) grade was purchased from Peboc (East-
man, UK). Pluronic F68 Prilled was obtained from Ruger
Chemical Co. Inc. (Irvington, New Jersey, USA). All other
reagents and chemicals were HPLC analytical grade, and were
used as received. Water was deionized and purified by a Milli-
Q Reagent Grade water system from Millipore Corporation
(Bedford, MX, USA).-lactide-co-glycolide)-co-PEG] diblock.
s types.
Lactic to glycolic
acid ratio
Content of
PEG (%)
Molecular weight
(Dalton)
1:1 10 5000
GA 1:1 10 6000
1:1 15 6000
1:1 5 5000
– – 18,000–28,000
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This study employed a modified emulsification–diffusion tech-
nique (Mora-Huertas et al., 2010). Briefly, the method requires
the preparation of three phases: organic, aqueous and dilution
phases. The organic phase was prepared by dissolving 20 mg of
AmB in 5 ml of the organic phase (acetone/dichloromethane;
(ACT/DCM: 6/1)) containing aliquot of PLGA–PEG copoly-
mer and 200 ll of 5 N HCl. The composition of the studied
AmB-NPs formulations is listed in Table 2. All the vehicles
used in this study were protected from light, either by using
amber containers or through covering containers with
aluminum foil. Miglyol was added to the organic phase, then
sonicated for 5 min and stirred until a clear solution was
obtained using a magnetic stirrer. The aqueous phase was pre-
pared by adding two types of stabilizer; polyvinyl pyrrolidone
(PVP) and pluronic (F-68), TPGS was added also. The organic
solution was slowly added (drop wise, for five minutes) to the
aqueous phase using a high speed stirrer (Ultra-Turrax T25,
IKA Labotecnik, Staufen, Germany). The organic emulsion
was then added to 200 ml of distilled water to induce diffusion
of the organic phase into the continuous phase, with mechan-
ical stirring at 60 C for 3 h. Each batch was prepared in trip-
licate. All formulations were freeze-dried under vacuum
(1.25 mBar) at 52 C (Labconco-Free zone 4.5, Kansas,
US) until complete dryness. Formulated dry NPs were stored
in the freezer (20 C) prior to further investigation.
For optimizing the formulation process, the effect of vari-
ous factors on the AmB-NPs formulations were investigated.
The effect of the stirrer speed (8000, 13,500 and 24,000 rpm)
on four different PLGA–PEG copolymer NPs were studied.
The effect of PVP concentration, miglyol-812 and TPGS
were also studied.
Furthermore, in this study polymer R 203 H (Poly D,L-lac-
tide) was included to assess the effect of pegylated copolymer.Table 2 Composition of AmB nanoparticles produced by emulsific
Batch No. Copolymer type Phases
Organic
Drug (m
A3 Diblock, 10% PEG RGPd 50105 20
A4 20
A5 20
A6 20
B3 Triblock, 10% PEG RGPt 50106 20
B4 20
B5 20
B6 20
C3 Diblock, 15% PEG RGPd 50155 20
C4 20
C5 20
C6 20
C7 40
E7 R 203 H 40
D3 Diblock, 5% PEG RGPd 5055 20
D4 20
D5 20
D6 20
a Each formula contains 200 mg polymer and 200 ll of 2 NHCL.
b Contains 0.5% pluronic-68.2.3. Physicochemical characterization of the nanoparticles
2.3.1. Particle size analysis and polydispersity index (PDI)
The cumulative mean of particle size and polydispersity index
(PDI) were determined by dynamic light scattering using Zeta-
sizer (Malvern Instruments, Worcestershire, UK). Typically,
after freeze drying of formulated batches of AmB-NPs, the
dried powder samples were suspended in deionized water and
sonicated before measurement. The obtained homogeneous
suspension was examined to determine the mean diameter, size
distribution and polydispersity index. Viscosity and the refrac-
tive index of the continuous phase were set to those specific to
water.
2.3.2. Fourier Transform Infra-Red Spectroscopy
The Fourier Transform Infra-Red (FTIR) spectra of each pure
component as well as the prepared freeze-dried AmB-NPs for-
mulations were analyzed using a FTIR spectrophotometer
(Perkin–Elmer-Spectrum 1600, Norwalk, USA). The FTIR
measurements were performed at wave numbers ranging from
450 to 4000 cm1 at constant rate of 10 C/min under an argon
purge. AmB samples were diluted with KBr powder. The IR
spectra were obtained in a KBr disk at ambient temperature.
2.3.3. Morphology of the nanoparticles
The dry samples of each prepared AmB-NPs formulation were
mounted onto metal stubs using double-sided adhesive tape.
The stubs were then vacuum coated with gold using fine coat
ion sputter under reduced pressure to render them electrically
conductive prior to examination by SEM (SEM, JEOL JSM-
6060 LV, Jeol Ltd., Tokyo, Japan). The accelerating voltage
was kept constant at 15 kV under an argon atmosphere.
Transmission electron microscopy (TEM, JEM-1011, Jeol
Ltd., Tokyo, Japan) was used to examine the morphology of
each prepared AmB-NPs formulation. The aqueous (water)ation–diffusion method using 24,000 rpm stirring rate (n= 3).
phasea Aqueous phaseb
g) Miglyol (%) PVA (%) TPGS (%)
– 1 –
2.5 1 –
2.5 1 5
2.5 4 5
– 1 –
2.5 1 –
2.5 1 5
2.5 4 5
– 1 –
2.5 1 –
2.5 1 5
2.5 4 5
2.5 4 5
2.5 4 5
– 1 –
2.5 1 –
2.5 1 5
2.5 4 5
294 B.T. AL-Quadeib et al.dispersion of the freeze-dried NPs were placed over a 400 mesh
copper grid covered with carbon film.
2.3.4. Differential scanning calorimetry (DSC)
Samples of AmB loaded nanoparticles were scanned to
determine the thermal properties of the AmB in its NP formu-
lations. Approximately 2 mg samples were accurately weighed
and placed into standard aluminum pans, which were hermet-
ically sealed. An empty pan was used as a reference. The tran-
sition temperature (Tc) and enthalpy of transition (DH) were
determined from the thermogram, generated by a differential
scanning calorimeter (Perkin Elmer DSC7, Perkin Elmer
Ltd., Norwalk, USA). The heating rate was 10 C/min from
30 to 200 C, with a closed-pan system under a stream of argon
gas flow, after which the system was cooled down at the same
rate from 200 to 30 C. The apparatus was calibrated with
indium 99.99%. In addition, DSC scans were performed for
each pure component of the formulations. All the samples
were freeze-dried before the measurements.
2.3.5. Determination of drug entrapment efficiency and
nanoparticles yield
Drug entrapment efficiency (DEE) of AmB in the NPs was
determined directly by measuring the amount of AmB
entrapped in the NPs. Briefly, a 10 mg sample of the freeze-
dried NPs was dissolved in 5 ml of DCM: ACN (1:6 v/v),
200 ll of 5 N HCl and the volume was made up to10 ml with
methanol:water (75:25 v/v). An aliquot of 1.25 ml of the stock
solution was mixed with 1 ml of nicardipine (IS, 10 lg/ml) and
the volume was 5 ml with methanol: water (75:25 v/v). Absor-
bance at 382 nm of diluted stock solution was determined and
the AmB concentration was calculated using a validated high
performance liquid chromatography (HPLC) method as
described below.
DEE (%w/w) = 100 * (Mass of recovered AmB-NPs/Ini-
tial mass of drug used in formulation)
Yield (% w/w) = (mass of AmB-NPs/total mass of poly-
mer and drug added) · 100
2.3.6. Drug release study
The quantitative in vitro release test was performed using US
Pharmacopeia XXXII dissolution apparatus 2 (paddle). The
dissolution was carried out in 500 ml of phosphate buffer con-
taining 2% sodium deoxycholate (pH 6.8 ± 0.1) at 50 rpm and
the temperature was maintained at 37 ± 0.5 C. A sample of
AmB NPs equivalent to 5.0 mg of AmB was placed on the sur-
face of the dissolution medium. At appropriate time intervals
(0.25, 0.5, 1, 2, 3, 4, 5, 6 and 24 h), 2.0 ml samples were with-
drawn from each vessel, mixed with 1.0 ml of IS (10 lg/ml) and
5.0 ml with methanol:water (75:25). The solution was filtered
through a 0.22 lm Millipore membrane filter and analyzed
using a validated HPLC assay as described below. The volume
was replaced each time with 2 ml of fresh medium kept at
37 ± 0.5 C to maintain a sink condition.
2.3.7. HPLC assay for in vitro study
The concentration of AmB was measured using a Waters
HPLC system equipped with a Waters 484 variable UV absor-
bance detector and a Waters 717 plus autosampler. Waters 515
solvent delivery system was used to operate the gradient flowthrough a Novapak C18 column (3.9 · 150 mm) packed with
5 lm spherical particles. The mobile phase consisted of aceto-
nitrile (40.5%): methanol (4.5%) acetic acid (0.2%) and 0.1%
triethylamine. Degassing was achieved by filtration through a
0.22 lm Millipore membrane filter and sonication for 10 min.
The injection volume was 75–100 ll and detection was at
382 nm. The mobile phase flow rate was 1.2 ml/min and the
run time was 5.0 min. Data were collected with an Empower
Pro Chromatography Manager Data Collection System. The
HPLC system was operated at ambient temperature. A daily
standard calibration curve (6 standards ranging from 0.5 to
10 lg/ml) was performed to determine the unknown AmB con-
centration for DEE and release. The assay was fully validated
for accuracy and precision according to USP guidelines (US
Food and Drug Administration (2006)). The percent intra-
day relative standard deviation (R.S.D.%) was <5%, and
the inter-day deviation (R.S.D.%) was <6% at three different
days (P> 0.05). The mean retention times of AmB and IS
were about 2.8 and 4.2 min, respectively. The detection limit
was 200 ng/ml.
2.3.8. Drug release kinetics
Drug release kinetics of AmB formulations were analyzed
using various dissolution models including; zero, first, Higuchi
and Korsmeyer–Peppas order. Release profile data were pro-
cessed and plotted according to the equations of different
models followed by regression analyses. The criterion for
selecting the most appropriate model was based on best good-
ness-of-fit (R2 values). The slope of each plot and its release
rate constant for each particular model were used to describe
the release rate mechanism.
2.4. Data and statistical analysis
All in vitro results were expressed as mean ± SD of at least
three replicates. The HPLC results of AmB were calculated
using linear regression without weighting, according to the
equation: Y= 0.041+ 0.379X, where, Y is the area under
the peak (AUP) ratio of the drug to the internal standard, a
is the intercept, b is the slope, and X is the concentration of
AmB. The R.S.D.% was calculated for all values. The Stu-
dent’s t-test was used to examine the concentration difference
at each day and one-way analysis of variance (ANOVA) was
employed to evaluate the reproducibility of the assay and the
dissolution from batch to batch using IBMSPSS Statistics
20. The level of confidence was 95%.
3. Results
3.1. Optimization of the AmB-NPs formulation process
A particulate method of NPs preparation is usually employed
considering the physicochemical properties of the drug to be
entrapped and route of administration to be given. For hydro-
phobic drugs, nano precipitation (Bilati et al., 2005) or an
emulsion–diffusion method is best suited (Dillen et al., 2006;
Italia et al., 2009; Mora-Huertas et al., 2010).
Selection of the proper organic solvent was the most chal-
lenging issue for ing AmB acetone/dichloromethane (6:1) was
found to be the most suitable agent for the drug and
Table 3 Influence of shearing rate on the mean particle size and poly dispersity index of AmB-NPs prepared by emulsification–
diffusion method.
Batch number Particle size (nm) ± SD Polydispersity index ± SD Stirring speed rpm DEE% Yield%
A1 1,068.1 ± 489.8 0.46 ± 0.1 8000 18.5 ± 3.3 67.3 ± 2.1
A2 451.2 ± 84.2 0.46 ± 0.1 13,500 16.4 ± 3.4 73.7 ± 1.2
A3 400.2 ± 62.1 0.64 ± 0.3 24,000 23.3 ± 7.3 75.0 ± 1.4
In vitro Optimization of Amphotericin Oral Nanoparticles 295PLGA–PEG copolymer, with the addition of 200 ll of 5 N
HCl, to ensure complete solubilization of AmB.
3.2. Factors affecting the particle size distribution
3.2.1. Effect of shearing rate
The relationship between stirring speed and mean particle size
(MPS) is shown in Table 3. Different speeds of mechanical stir-
ring – 8000, 13,500 and 24,000 rpm – were tested. The NPs size
was inversely proportional to the stirring speed. A significant
reduction in the NPs size (from 1068.1 ± 489.8 to
400.2 ± 62.1 nm) was observed on increasing the shearing rate
from 8000 to 24,000 rpm for formulations A1 to A3 using
RGPd 50105 polymer. The same trend was observed using
different polymers, therefore throughout the study, the
24,000 rpm was used as the shearing rate for the nanoparticles
preparations.
3.2.2. Effect of surfactant and emulsifier used
In optimization trials, the main basic constituents of AmB-
NPs formulations were AmB (20 mg), PVP (1%) and F-68
(0.5%). The different composition of NPs investigated during
the study and their effect on the DEE%, yield% and the size of
the NPs are summarized in Tables 3 and 4. It was noticed that
all the produced AmB NPs batches have homogenous distribu-
tion with PDI of <0.5, were in the nanometer size range with
narrow size distribution and without polymer flakes or visible
oil droplets.Table 4 Influence of different composition parameters on the mean
emulsification–diffusion method.
Batch number Particle size (nm) ± SD Poly dis
A3 400.2 ± 62.1 0.64 ± 0
A4 126.8 ± 27.3 0.53 ± 0
A5 105.2 ± 9.3 0.26 ± 0
A6 93.3 ± 5.7 0.51 ± 0
B3 107.4 ± 61.9 0.53 ± 0
B4 97.4 ± 10.2 0.39 ± 0
B5 69.4 ± 14.7 0.24 ± 0
B6 55.4 ± 5.9 0.26 ± 0
C3 57.2 ± 7.5 0.25 ± 0
C4 36.8 ± 7.6 0.28 ± 0
C5 27.0 ± 5.6 0.34 ± 0
C6 23.8 ± 4.8 0.31 ± 0
C7 25.3 ± 2.7 0.31 ± 0
E7 539.9 ± 51.1 0.35 ± 0
D3 515.6 ± 30.7 0.37 ± 0
D4 418.8 ± 28.2 0.32 ± 0
D5 344.4 ± 38.4 0.26 ± 0
D6 318.4 ± 36.8 0.36 ± 0
A: RGPd 50105, B: RGPt 50106, C: RGPd 50155, D: RGPd 5055.Four PLGA–PEG copolymer were investigated throughout
the study RGPd 50105 (A), RGPt 50106 (B), RGPd 50155 (C)
and RGPd 5055 (D). Note, the letter indicates the copolymer
used, while numbers were used to indicate the composition
of the formulation; the same composition will have same
number.
For basic component formulations, batches containing
copolymer C had the lowest MPS (Table 4) among the other
tested formulations. Under the same condition copolymer D
had the highest MPS within the tested batches.
The addition of miglyol-812 (2.5%) to the basic component
of each copolymer (Batches A4, B4, C4, D4) during the prep-
aration process (Table 4), led to a significant reduction in MPS
(P< 0.05) in all batches. The size reduction was in the direc-
tion of A(68%) > C (35%) > D (18.9%) > B (8.5%). There-
fore, miglyol-812 (2.5%) was added to the basic composition
of the AmB-NPs starting from batches with number 5.
The same trend was observed on adding TPGS (5% w/v)
causing further reduction in MPS of A and D (16.6% and
17.9%, respectively) and B and C (27.8% and 27%, respec-
tively), TPGS was also added to the basic component of the
AmB-NPs formulation starting from batches with number 6.
Moreover, increasing the concentration of PVP from 1% to
4%, the MPS of AmB-NPs formulation was also decreased the
MPS in this order B, A, C, D (21.5%, 11.5%, 11.1% and 7.5%
respectively).
Interestingly, changing the PLGA–PEG copolymer to
203H polymer (non-pegylated) formulation E7, caused a sig-
nificant increase in the MPS > 95%.It should be mentionedparticle size and poly dispersity index of AmB-NPs prepared by
persity index ± SD DEE% Yield%
.3 23.3 ± 7.3 75.0 ± 1.4
.2 23.9 ± 1.1 81.3 ± 2.2
.1 24.8 ± 4.1 82.5 ± 1.3
.3 37.8 ± 7.5 83.7 ± 1.4
.3 20.4 ± 1.4 74.8 ± 1.5
.1 21.2 ± 7.1 77.1 ± 2.3
.1 36.9 ± 2.4 78.9 ± 2.4
.1 37.5 ± 1.7 80.9 ± 1.7
.1 25.9 ± 0.5 82.5 ± 1.1
.1 29.9 ± 6.2 83.8 ± 1.2
.1 40.6 ± 10.9 87.5 ± 1.1
.0 48.3 ± 4.2 90.6 ± 0.5
.0 56.5 ± 3.9 93.2 ± 0.5
.1 27.2 ± 3.2 67.4 ± 0.8
.0 24.3 ± 2.3 85.5 ± 1.4
.1 24.4 ± 2.7 86.9 ± 2.2
.10 27.4 ± 2.5 88.1 ± 1.7
.10 39.4 ± 9.2 89.6 ± 1.0
296 B.T. AL-Quadeib et al.that no more than 40 mg of AmB could be incorporated in
these formulations (C7), with no significant effect on MPS.
Therefore, formulations A6, B6, C6, C7, E7 and D6 with the
lowest MPS were selected for the next in vitro characterizations
steps.
3.3. Drug encapsulation efficiency and nanoparticles yield
The DEE of the AmB NPs was found to be inversely propor-
tional to the MPS (Table 4). The minimum DEE for all formu-
lated batches was 20% (B3) while the maximum encapsulation
was 56.5% (C7) which is considered suitable for delivering a
therapeutically active dose. Meanwhile, for the best selected
formulations, the DEE was in the following order
56.5%> 48%> 39%> 37%> 32%in corresponding to
C7, C6, D6, A6 and B6, respectively. The non-pegylated poly-
mer (E7) shows a DEE of 27%. However the highest yield of
AmB-NPs was 93% (C7) while the lowest one was 74% (B6).Figure 3 SEM images for AmB-NPs containing 20 mg AmB and pre
(B6); RGPd 50155 copolymer (C6); GPd 5055 copolymer (D6) and A
(C7) and R-203-H polymer (E7) batches.3.4. Poly disparity index
PDI values, range from 0 to 1; a higher value indicates a less
homogenous NP size distribution (Galindo-Rodriguez et al.,
2004). Tables 3 and 4 indicate that PDI in all batches is almost
<0.5; which means that all batches had an homogenous distri-
bution of nanoparticles in water.3.5. Scanning electron microscopy (SEM) and transmission
electron microscopy (TEM)
Representative SEM images of AmB-NPs selected formula-
tions (Fig. 3, A6, B6, C6, C7, E7 and D6), demonstrates
aspherical and discrete NPs of <1000 nm which consistent
with the Zeta sizer measurement of MPS (Tables 3 and 4)
and the TEM analyses of the freeze-dried AmB-NPs (Fig. 4,
A6, B6, C6, C7, E7 and D6).pared with RGPd 50105 copolymer (A6); RGPt 50106 copolymer
mB-NPs containing 40 mg AmB and prepared with RGPd 50155
Figure 4 TEM images for AmB-NPs containing 20 mg AmB and prepared with RGPd 50105 copolymer (A6); RGPt 50106 copolymer
(B6); RGPd 50155 copolymer (C6); GPd 5055 copolymer (D6) and AmB-NPs containing 40 mg AmB and prepared with RGPd 50155
(C7) and R-203-H polymer (E7) batches.
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FTIR was used to identify any change in the drug in formula-
tions compared to the pure drug. The important bands of
AmB are listed in Table 5. Fig. 5, displays the FTIR spectra
for AmB NPs prepared by RGPd 50155 copolymer (C). It
can be observed that the FTIR spectrum for the pure AmB
is different to that of the AmB-NPs, since pure AmB crystals
show characteristic sharp bands at 1691, 1557 and
1009 cm1, due to a C‚O stretch band; NH2 in-plane bend,
polyene C‚C stretch band and C–H bend out of plane bend
(trans polyene), respectively (Asher and Schwartzman, 1977;
Nahar and Jain, 2009). In case of the freeze-dried batches of
AmB-NPs, in particular, the carbonyl-stretching band was lost
(Fig. 5) likely due to an interaction between the AmB and the
polymer used. Similar interactions were observed with the
other three copolymers (data not shown).3.7. Differential scanning calorimetry
Fig. 6 shows the thermogram of the drug and copolymer each
separately. The DSC thermogram of drug showed a broad
endothermic peak due to the loss of moisture starting from
30 to 100 C attributed to the loss of adsorbed water (AmB
is hygroscopic in nature). Two characteristic endothermic
peaks were observed for AmB at 168.5 and 213.4 C. Similar
findings were observed others (Asher and Schwartzman,
1977; Janoff et al., 1988; Madden et al., 1990). The DSC traces
for the pure copolymer did not show any endothermic peaks
observed at in the melting region of the drug. Meanwhile,
characteristic peaks for the copolymer at 66.3–68.7 C were
seen, corresponding to its phase transition temperature (tm).
Similar findings have been obtained by (Vega et al., 2012).
However, the complete disappearance of the characteristic
peaks for AmB from the thermograms of the FD products
Table 5 Important bands of IR spectrum of AmB.
Frequencies
(cm1)
Functional group present
3390 C–H stretch (polyene) and O–H stretch
(strongly H-bonded)
2940 C–H3 asymmetric shoulder stretch band
1691 Sharp C‚O stretch band, NH2 in-plane bend
1557 Polyene C‚C stretch band
1402 C–H bend in polyene ring
1069 C‚O asymmetric stretch
1009 C–H bend out of plane bend (trans polyene)
851 C–H bend in pyranose ring vibration
Figure 5 FTIR spectra for AmB-NPs formulatio
Figure 6 DSC thermograms of Ampho
298 B.T. AL-Quadeib et al.(Fig. 6), indicating the loss of the crystalline lattice of the drug
and formation of an amorphous state as a result of the inclu-
sion of the drug inside the polymers (Al-Assady et al., 2013).
3.8. In vitro release of Amphotericin
The in vitro release study of AmB was conducted in phosphate
buffer with 2% sodium deoxycholate (Choi et al., 2008) was
selected for release studies. This medium was able to maintain
sink conditions, and thus was selected for release studies. The
drug release pattern for 24 h is depicted in Fig. 7. Release
profile indicated biphasic release of AmB from the NPs. In first
phase (6 h, r> 0.9) there was an initial rapid release of aboutns prepared by RGRGPd50155 copolymer (C).
tericin B and pure copolymer used.
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
100.00
-2.00 2.00 6.00 10.00 14.00 18.00 22.00 26.00
A6
B6 
C6
C7
E7
D6 
Figure 7 In vitro drug release behavior for AmB-NPs. Data points with standard deviation error bars represent the mean values of three
samples.
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from 6 to 24 h where about 11% was released. According to
the results obtained, it was found that there no lag time which
indicates a burst in drug release during the first 15 min (about
4–10%) of the adsorbed drug on the NPs. The highest drug
release within 24 h was obtained with C6 (61%), while the low-
est was A6 (31%).
The results of modeling for the release profile are given in
Table 6. The correlation coefficient (r) and release rate con-
stant (K) were calculated for each release model. Higuchi, as
well as Korsmeyer–Peppas (n= 0.5) models, show the highest
correlation for all selected formulations. It should be men-Table 6 Modeling of Amphotericin release from different formulat
Formulation code Zero-order (Qt=Q0 + kt) First-order LnQt =L
R2 K R2 K
A1 0.1863 1.538 0.0395 0.
A2 0.4214 1.203 0.2271 0.
A3 0.1271 1.307 0.2817 0.
A4 0.1558 1.510 0.0613 0.
A5 0.1974 1.676 0.0651 0.
A6 0.7106 1.777 0.3564 0.
B3 0.3081 1.538 0.0615 0.
B4 0.2749 1.941 0.0538 0.
B5 0.0139 2.211 0.3448 0.
B6 0.4388 2.172 0.0314 0.
C3 0.4744 2.785 0.1308 0.
C4 0.5561 2.696 0.0627 0.
C5 0.4713 2.671 0.1123 0.
C6 0.0243 3.448 0.6637 0.
C7 0.2879 3.229 0.4004 0.
C9 0.2356 2.007 0.4714 0.
D3 0.2474 1.622 0.0041 0.
D4 0.3310 1.491 0.0866 0.
D5 0.0910 1.576 0.1378 0.
D6 0.4197 2.094 0.0324 0.
R2, is the correlation coefficient; K, is the release rate constant for respectiv
initial amount of drug k is release rate constants of respective equation.tioned that doubling the drug content in the formulation
(C7) shows no significant difference (P> 0.5) on the drug
release. Therefore, formula C6 was selected for the next
in vivo (PO) study.4. Discussions
The first challenge in developing any AmB drug delivery sys-
tem was its poor solubility in any solvents, which has been
overcome by co-solvation and through lowering of the pH
(Venier-Julienne and Benoit, 1996; Nahar and Jain, 2009).ions.
nQ0 + kt Higuchi Qt= k
p
t Korsmeyer–Peppas Qt/Q1=
Ktn (n= 0.5, 0.75, 1.25)
R2 K R2 K
020 0.7824 6.909 0.9229 1203.34
015 0.7861 5.433 0.9174 6283.477
016 0.9268 5.694 0.9162 1053.077
020 0.8232 6.784 0.8789 4329.172
023 0.8599 7.459 0.9730 15.335
025 0.7121 8.059 0.9671 6.660
020 0.7751 6.959 0.7479 5762.237
028 0.7967 8.750 0.8097 11841.066
034 0.8860 9.772 0.9095 109.169
033 0.8120 9.634 0.9719 8.122
054 0.7705 12.604 0.9568 12.331
053 0.7019 12.365 0.8887 1685.306
051 0.7341 12.200 0.9504 4592.819
089 0.8373 15.362 0.9036 38975.364
071 0.8329 14.378 0.9034 36540.313
029 0.8872 8.767 0.8762 1579.928
022 0.8471 7.235 0.9970 225.363
019 0.8234 6.680 0.8041 14294.643
021 0.8829 6.984 0.9648 9338.453
032 0.8111 9.410 0.9648 9338.453
e model. Where, Qt is the amount of drug released at time t, Q1 is the
300 B.T. AL-Quadeib et al.The second challenge was to improve the drug encapsula-
tion efficiency (DEE) which determines the efficiency of the
system to hold the drug as well as overall amount of polymer
in carrier system required to deliver a particular amount of
drug. The best developed formulation in this study has a
DEE of 56.5% which is >5-fold better compared to the lipo-
somal AmB (Ambisome) on the market, with a DEE of
11.72% (Jain and Kumar, 2010). Therefore, novel oral AmB-
NPs have been developed using a modified emulsification dif-
fusion method using pegylated (PLGA–PEG15% -diblock
copolymer) which is characterized by a simple preparation
procedure, high encapsulation efficiency and high reproduc-
ibility (Cauchetier et al., 2003; Mora-Huertas et al., 2011).
The effect of main process variables on formulation parame-
ters have been studied to obtain AmB-NPs with a narrow size
distribution, low PDI and maximum DEE.
AmB formulation with PLGA–PEG diblock copolymer
(RGPd 50155 with 15% PEG) has produced a significant
reduction (>70%) in the MPS compared to the other devel-
oped AmB-NPs. This can be attributed to the higher percent-
ages of the PEG loaded in the copolymer. Similar results were
observed by (Buske et al., 2012). Additionally, the same poly-
mer has shown that the highest drug content in comparison
with other developed formulations. This is in agreement with
(Mallarde´ et al., 2003; Buske et al., 2012) in that the percentage
of PEG has a significant effect on the size reduction of formu-
lated NPs. Meanwhile, in comparing diblock versus triblock
with the same percentage of the PEG (10%) the study has
shown that triblock copolymer is better by about 30% than
the diblock copolymer (Buske et al., 2012; Zhang et al.,
2014). Therefore, PLGA–PEG 15%diblock copolymer was
the optimum formulation in these studies.
The addition of miglyol to the organic phase could lead to
further reduction in particle size due to the fact that miglyol-
812 (Caprylic/Capric Triglyceride mixture) increases emulsifi-
cation associated with the production of finely dispersed emul-
sions ((Pouton, 1985). Additionally, solvent capacity for less
hydrophobic drugs can be improved by blending with triglyc-
erides, so miglyol could dissolve higher amounts of AmB. This
conclusion is in agreement with the finding of (Patil et al.,
2004) with ketoprofen and (Garcia-Fuentes et al., 2005) with
tripalmitin.
Proper selection of stabilizers or additives in the aqueous
phase, with high affinity for hydrophobic NPs surface, is a
key element in preventing such small particles with high sur-
face area from aggregating. PVA is the most commonly used
emulsifier because it generates particles that are relatively uni-
form, small and easy to re-disperse in aqueous medium (Sahoo
et al., 2002; Saadati and Dadashzadeh, 2014). PVP is used in
the present work as stabilizer to protect AmB-NPs from aggre-
gation during the preparation.
Further reduction in MPS has been observed with the addi-
tion of a second emulsifier (TPGS) which is a water-soluble
derivative of natural vitamin E, with amphiphilic bulk struc-
ture. Its large surface area makes it an excellent emulsifier,
and solubilizer of hydrophobic drugs (Zhang et al., 2007) for
fabricating nano/microparticles with high drug entrapment
efficiency and high emulsification efficiency (Ke et al., 2005).
This is in agreement with the study of (Zhang et al., 2007)
on doxorubicin.
Therefore, the use of two emulsifying agents – PVP and
Vitamin E (TPGS) – in an AmB formulation led to a signifi-cant reduction in particle size and increase in DEE than using
PVP alone. This is quite possible since TPGS has tendency to
migrate to the surface of nanoparticles (Si-Shen et al., 2004)
and the amphiphilic nature of TPGS shows that its hydropho-
bic moiety was more influential than its hydrophilic moiety.
Therefore, when TPGS was used as a second component of
the matrix material with PVP, the interaction or affinity
between the polymer matrix and the drug was enhanced and
thus caused a further reduction in particle size (Si-Shen
et al., 2004).
Pluronic F68 (also known as Poloxamers 188) is a hydro-
philic non-ionic surfactant that has been widely used as wet-
ting, solubilizing agent and surface adsorption excipient
(Newa et al., 2007). They have been employed to enhance
the solubility, dissolution and bioavailability of many poorly
water soluble drugs – including ibuprofen – using various tech-
niques (Yu et al., 2007). For some drugs, the improvement in
solubility using Pluronic was higher compared to the other
meltable polymers such as PEGs or complex forming agents
such as cyclodextrins (Chutimaworapan et al., 2000). In this
study, a similar finding (reduction in MPS) was observed by
adding F68. Some reports demonstrated that Pluronic F68
performs better than other carriers (e.g., PVP and hydroxyl
propyl methylcellulose (HPMC)) in terms of dissolution rate
enhancement because it has dual roles in the solid dispersion
formula, one as a polymeric carrier and the other as a surface
active agent (He et al., 2011). Additionally, pluronic F68,
offered an additional steric stabilization effect by preventing
aggregation of the fine particles in the colloidal system (Mei
et al., 2009). In this sense, Pluronic F68 may act as a co-emul-
sifier in the fabrication process, resulting in smaller particle
size and narrow size distribution.
The morphology of AmB-NPs was spherical and the results
of the TEM observations support this finding. Specific peaks
associated with AmB were lost when present in the polymer
as determined by FTIR. These results indicate that an interac-
tion takes place between the drug and polymer. The FTIR
spectral changes were attributed to electrostatic interaction
between carboxylic acid group of the AmB and PLGA–PEG
copolymer, turning the O–H bond of the carboxylic group into
a new ether bond, which was represented by the peak at
1125 cm1. The FTIR spectroscopy demonstrate the successful
attachment of AmB to PLGA–PEG copolymer, similar finding
with AmB attached to functionalized carbon nanotubes (f-
CNTs) (Prajapati et al., 2011).
AmB-NPs formulations, which can be considered a matrix
containing drug, is anticipated to release the drug by a diffu-
sion mechanism. This finding is in agreement with (Italia
et al., 2009).
Release study behavior of AmB-NPs shows biphasic release
where the first rapid phase of release lasted for 6 h, followed by
a slow diffusion order rate of release for the next 24 h. The first
phase of AmB release may be due to dissolution and diffusion
of the drug that was poorly entrapped in the Copolymer NPs
matrix, while the slower and continuous release may be attrib-
uted to the diffusion of the drug localized in the core of the
PLGA–PEG copolymer.
The possible reason for the significantly higher release rate
in C batches may be corresponds to a lowest MPS of the pre-
pared AmB-NPs in comparison with other NPs formulations,
providing maximum surface area for interaction with dissolu-
tion media. The mechanism of drug release may be assumed, in
In vitro Optimization of Amphotericin Oral Nanoparticles 301that AmB-NPs possess greater hydrophilicity, leading to a
greater tendency for the release medium to penetrate the par-
ticle core to cause swelling. The release rate of the drug and
its appearance in the dissolution medium was governed by dif-
fusion of drug across NPs.
5. Conclusion
The selected AmB NPs formulation showed a narrow size dis-
tribution with mean particle size which could be systemically
varied according to the preparation conditions. The variation
of the NP mean particle size was also associated with the phys-
icochemical properties of the content of the organic and aque-
ous phases used for NP formulation.
The feasibility of using three surfactants and stabilizers on
the MPS and DEE was clear that the best significant. This was
related to the percentage of PEG in the polymer as well as the
solubilizing agent added to the formulations. Addition of
higher concentrations of PVP1, Vitamin-E (TPGS) as well as
miglyol led to significant increases in drug entrapment effi-
ciency as well as to increases in the in vitro release in compar-
ison to other formulations.
Based on these results, it can be concluded that the formu-
lations developed could be a viable, effective and good alterna-
tive to other carriers as a novel oral delivery of AmB. Ongoing
in vivo studies are underway which ascertain the oral absorp-
tion of the developed formulations and the possible future
marketing as oral dosage form.
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